Recombinant Human TPO Protein (N, C-6His)

Name: Recombinant Human TPO Protein (N, C-6His)
Brand: Beta LifeScience
SKU: BL-0277NP
Availability: InStock

BL-0277NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: Cytokines, Cytokines and growth factors, Other cytokines, Recombinant proteins, Recombinant thrombopoietin (tpo) proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Thrombopoietin is produced by our Mammalian expression system and the target gene encoding Ser22-Gly353 is expressed with a 6His tag at the N-terminus, 6His tag at the C-terminus.
Accession	P40225
Synonym	Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; Myeloproliferative leukemia virus oncogene ligand; THPO
Gene Background	Thrombopoietin (TPO) is a glycoprotein hormone which belongs to the EPO/TPO family. It produced by the liver and kidney which regulates the production of platelets. TPO stimulates the production and differentiation of megakaryocytes, the bone marrow cells that bud off large numbers of platelets. Lineage-specific cytokine affects the proliferation and maturation of megakaryocytes from their committed progenitor cells. It acts at a late stage of megakaryocyte development. It may be the major physiological regulator of circulating platelets.
Molecular Mass	37.3 KDa
Apmol Mass	70-90 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM Tris, 150mM NaCl, pH 8.0.
Endotoxin	Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Lineage-specific cytokine affecting the proliferation and maturation of megakaryocytes from their committed progenitor cells. It acts at a late stage of megakaryocyte development. It may be the major physiological regulator of circulating platelets.
Subcellular Location	Secreted.
Protein Families	EPO/TPO family
Database References	HGNC: 11795 OMIM: 187950 KEGG: hsa:7066 STRING: 9606.ENSP00000204615 UniGene: Hs.1166
Associated Diseases	Thrombocythemia 1 (THCYT1)

Gene Functions References

The expression of TPO and c-Mpl was significantly decreased in the cITP group compared to the nITP group, suggesting that TPO and its receptor may play important roles in childhood cITP pathogenesis. PMID: 29313460
FISH study showed no cytogenetic abnormalities in any of the analyzed cases. PMID: 16682284
results confirm that TPO acts as an acute phase protein but exclude the possibility that it is uniquely responsible for thrombocytosis of inflammatory disorders, which might recognize in IL-6 a credible candidate as a cooperating factor. PMID: 18041648
evidence for the presence of a low TPO gene expression transcript in B-CLL cells; early B-cell CLL circulating level of TPO does not provide a useful insight into the complex interrelationship of prognostic variables PMID: 18203013
Thrombopoietin levels are increased in patients with severe acute respiratory syndrome; TPO may have a role in thrombocytosis, which frequently develops from thrombocytopenia in SARS patients PMID: 18314161
separate binding sites on the Mpl receptor for TPO and hNUDC identified PMID: 20529857
Tensin2 is an important new mediator in TPO/c-Mpl pathway; Tensin2 becomes phosphorylated in a TPO dependent manner. PMID: 21527831
perioperative TPO dynamics are associated with postoperative LD. Postoperative TPO levels were found to be lowest in high-risk patients (HCC patients undergoing major resection) but showed an independent predictive value. PMID: 25611592
Data indicate thrombopoietin (TPO) as potential early prognostic biomarker in acute pancreatitis (AP) patients. PMID: 28079612
These studies demonstrate that biallelic loss-of-function mutations in THPO cause bone marrow failure, which is unresponsive to transplant due to a hematopoietic cell-extrinsic mechanism. PMID: 28559357
Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models PMID: 28456746
High Thrombopoietin expression is associated with immune thrombocytopenia in pregnancy. PMID: 26840092
Colorectal cancer tumor-initiating cells (TICs) expressing CD110, the thrombopoietin (TPO)-binding receptor, mediate liver metastasis. We show that TPO promotes metastasis of CD110+ TICs to the liver by activating lysine degradation. PMID: 26140605
decreased TPO levels or decreased bone marrow production of platelets may not be a cause of thrombocytopenia in chronic hepatitis C PMID: 25728497
WASP, RUNX1, and ANKRD26 genes are important for normal TPO signaling and the network underlying thrombopoiesis. PMID: 26175287
Data suggest that elevated serum level of thrombopoietin may serve as unfavorable marker of stage of multiple myeloma. PMID: 25323752
The regulation of OCs by TPO highlights a novel therapeutic target for bone loss diseases and may be important to consider in the numerous hematologic disorders associated with alterations in TPO/c-mpl signaling PMID: 25656774
TPO was greatly enhanced in HPT in comparison with ITP patients (958 +/- 659 and 11 +/- 27 pg/ml, p < 0.001). In the ITP group a reverse correlation was detected between TPO and glycocalicin (r = -0.373, p = 0.006). PMID: 25472766
observations suggest that NRP-1 is involved in megakaryocytopoiesis through complex formation with PDGFRs, and that NRP-1-PDGFR-complexes may contribute to effective cellular functions mediated by TPO and PDGF in megakaryocytic cells PMID: 25744030
An Arg->Cys substitution at residue 38 or residue 17 excluding the 21-AA signal peptide of the receptor binding domain was found in a family with aplastic anemia. Adding a 5th cysteine may disrupt normal disulfide bonding & receptor binding. PMID: 24085763
increased plasma thrombopoietin levels were associated with a favorable prognosis of bone marrow failure and could, therefore, represent a reliable marker for a benign subset of myelodysplastic syndrome. PMID: 23403320
Increased TPO levels may increase both platelet count and platelet size, resulting in more hemostatic tendency, which may contribute to the progression of ischemic stroke. PMID: 22327824
Platelet count and serum thrombopoietin level as predictors for morbidity and/or mortality in thrombocytopenic neonates. PMID: 22980223
Data indicate increased levels of serum thrombopoietin (TPO) were found in necrotizing pancreatitis. PMID: 22698803
Mutation in the THPO gene is not associated with aplastic anaemia in Japanese children. PMID: 22686250
Thrombopoietin is a biomarker and mediator of cardiovascular damage in critical diseases [review] PMID: 22577249
Findings establish that Clock regulates Thpo and Mpl expression in vivo, and demonstrate an important link between the body's circadian timing mechanisms and megakaryopoiesis. PMID: 22284746
Overstimulation of the THPO pathway might therefore predispose to clonal hematopoietic disease and to congenital abnormalities. PMID: 22453305
Data show that serum thrombopoietin levels in the affected family members were significantly higher than in the non-affected family members or healthy controls. PMID: 22194398
pattern of megakaryocytopoiesis is associated with up-regulated thrombopoietin (TPO) signaling through mammalian target of rapamycin (mTOR) and elevated levels of full-length GATA-1 and its targets PMID: 21304100
Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. PMID: 21262827
Findings thus suggest that decreased thrombopoietin production accompanying liver dysfunction may be related to thrombocytopenia besides myelosuppression in anorexia nervosa with malnutrition. PMID: 19810087
TPO negatively modulates cardiac inotropy in vitro and contributes to the myocardial depressing activity of septic shock serum PMID: 20467749
Overexpreeeion of human thrombopoietin increased the platelet level in the transfected mice. PMID: 11877062
Mutations in the 5' untranslated region of the TPO gene are not the cause of the normal or elevated TPO levels in acquired essential thrombocythemia. PMID: 11860444
REVIEW: central role in the pathogenesis of idiopathic thrombocytopenic purpura (ITP), andother immune-mediated thrombocytopenias. PMID: 11913997
While there is increased platelet turnover in patients with chronic renal failure, the kidney does not seem to play a major role in the overall Tpo production in the body. PMID: 11960394
binding to platelet thrombopoietin receptor is directly involved in human thrombopoietin plasma level regulation PMID: 11961237
Flt3/Flk-2-ligand in synergy with thrombopoietin may slow down megakaryocyte development by causing increased proliferation of megakaryocyte progenitor cells. PMID: 11983110
In the presence of EPO and SCF and/or IL-3, TPO enhances bone marrow erythropoiesis in cell cultures derived from patients with Diamond-Blackfan anemia. PMID: 12041668
Thrombopoietin activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets. PMID: 12135673
The endogenous levels of TPO, IL-6 and IL-8 are elevated in the thrombocytopenic patients with AML and MDS. PMID: 12187073
induces megakaryocyte-specific glycoprotein VI promoter and its regulation by GATA-1, Fli-1, and Sp1 PMID: 12359731
no difference was found in the cord blood level of thrombopoietin between infants born to mothers with pregnancy-induced hypertension and those without PMID: 12381927
review of TPO role in thrombopoiesis, signal transduction, cellular proliferative and anti-apoptotic mechanisms increasing megakaryocyte numbers PMID: 12430879
levels in children with acute and chronic idiopathic thrombocytopenic purpura and its relationship with mega-dose methylprednisolone therapy PMID: 12468916
Tpo concentrations in plasma samples taken concurrently from the right ventricle, the pulmonary artery, and the left ventricle showed there were positive correlations between the Tpo levels and pulmonary artery systolic pressure. PMID: 12487786
TPO stimulation of a megakaryocyte cell line activated lyn kinase, shown to be involved in the transduction pathway of the TPO proliferative signal. PMID: 12495897
Production of this protein in human hepatic cell cultures is not affected by IFN-alpha, IFN-beta, and IFN-gamma. PMID: 12581491
c-mpl mutations are the cause not only for the hypomegakaryocytic thrombocytopenia, but also for the development of an aplastic anemia (AA) in patients with CAMT PMID: 12799278

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.